Adempas (riociguat) - Important Safety Infomation from Bayer Pharma AG and MSD as approved by the HPRA

Notice type: 3rd Party Publications

Date: 07/07/2016


Problem Or Issue:
Important Safety Information communication from Bayer Pharma AG and MSD on Adempas (riociguat): New contraindication in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP).

Important Safety Information - Adempas (riociguat)


« Back